reports
IMV Inc: 2 directors
Two Directors at IMV Inc bought 120,000 shares at 1.850CAD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
IMV Inc. Announces Pricing of Public Offering
IMV Inc. Announces Pricing of Public Offering DARTHMOUTH, Nova Scotia, March 01, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the pricing of its previously-announced underwritten public offering (the “Offering”) of 4,900,000 common shares at a price to the public of Cdn$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately Cdn$26,705,000 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, t...
IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public O...
IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares DARTMOUTH, Nova Scotia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated June 5, 2018 (the “Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in the provinces of Briti...
IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Canc...
IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for developing DPX-Survivac as a monotherapy in certain ovarian cancer patients DARTMOUTH, Nova Scotia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced updates on its clinical progra...
IMV to Present at 2019 BIO CEO & Investor Conference
IMV to Present at 2019 BIO CEO & Investor Conference DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the in New York City, NY. This event will take place February 11-12, 2019, at the New York Marriott Marquis. , is scheduled to present a corporate overview and update on Monday, February 11, at 2:45 p.m. ET in the Herald/Soho room. His presentation will be available on IMV’s website at following the meeting. Now in its 21st year, the BIO CEO & Investor ...
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes F...
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial evaluating neoepitopes formulated in the Company’s proprietary DPX delivery platform in patients with ovarian cancer. The study is part of the Company’s DPX-NEO program, which is an ongoing collaboration between UConn Health and IMV to develo...
IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Cl...
IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress 73% of tumor regressions and 80% of clinical responses were observed in a subpopulation defined by a clinical biomarker based on Baseline Tumor Burden All durable clinical responses continued beyond the one year of treatment, surpassing the progression-free interval from patients’ previous chemotherapy treatment New data supports the correlation between DPX-Survivac’s novel T-cell activating mechanism of action and tumor regressions IMV to ho...
IMV Announces Updated Clinical Data Presentation for Lead Candidate DP...
IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018 IMV to host an investor call on Thursday, December 13 at 8:30 a.m. ET to discuss the presentation DARTMOUTH, Nova Scotia, Dec. 10, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that investigators will present data via a poster presentation at the this year’s . The conference will take place on December 13 – 16 in Geneva Switzerland at the Palexpo, ...
IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Co...
IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications DARTMOUTH, Nova Scotia, Dec. 05, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Marc Jasmin has joined the Company in the newly created role of Senior Director, Investor Relations and Communications. For the last 15 years, Mr. Jasmin has served in a broad range of investor and communications-focused positions. His experience includes overseeing the investor relations department of Cascades (CAS/TSX) and serving as Director, Inv...
IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research a...
IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018 DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV program at “” The conference will take place in Miami, Florida, from November 29 - 30, 2018 at the Marriott Miami Biscayne Bay. Members of IMV’s leadership will share data via an oral presentation as well as a poster session. Details are as follows: Name: ‘Evaluation of the therapeutic potential of antibody...
IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian...
IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer IMV Will Host an Investor Call Today at 8:00 a.m. ET to Discuss the Updates to Its Clinical Program DARTMOUTH, Nova Scotia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced an amendment to its phase 1b/2 clinical trial evaluating the safety and efficacy of IMV’s lead candidate, DPX-Survivac, in combination with either 100 mg or 300 mg of epacadostat in patients with recurrent ovarian cancer. Review of new data from the phase 1b p...
IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference DARTMOUTH, Nova Scotia, Nov. 15, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that and will present a corporate update at the Annual , which takes place from November 27–29 in New York, NY. IMV’s presentation details include: Date: Tuesday, November 27, 2018Time: 9:10–9:25 a.m. ETLocation: Staten Island Track, Kennedy 1 Ballroom, 4th Floor, Lotte New York PalaceA live webcast of the presentation will be accessible via the following URL:...
Veteran Oncology Biotechnology Executive and Third Rock Ventures Entre...
Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors DARTMOUTH, Nova Scotia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has appointed seasoned biopharmaceutical executive Markus Warmuth, MD, to its Board of Directors. Dr. Warmuth currently serves as an Entrepreneur in Residence at the life science venture capital firm Third Rock Ventures. He brings more than 20 years of drug discovery experience and scien...
IMV Inc. Announces Q3 2018 Financial Results and Investor Conference C...
IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details Achieved Initial Positive Data from Phase 2 Clinical Trial in DLBCL with MerckEntered into Collaboration with Merck on Phase 2 Basket Trial Across Five IndicationsAttained Multiple Milestones in Clinical Trial With Incyte CorporationWill Host Conference Call Today at 8 a.m. ET DARTMOUTH, Nova Scotia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for the three- and nine-month period ended ...
IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Ear...
IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018 DARTMOUTH, Nova Scotia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, November 2, 2018 at 8:00 a.m. ET to discuss the company’s third quarter financial and operational results. The dial-in number for the conference call is (844) 461-9932 (U.S. and Canada) or (636) 812-6632 (international) with the conference ID: 5779058. Thos...
IMV Inc. to Present at Upcoming Investor Conferences
IMV Inc. to Present at Upcoming Investor Conferences DARTMOUTH, Nova Scotia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that and will present a corporate update at two upcoming investor conferences. , San Francisco, CA Date: Thursday, October 18, 2018Time: 9:00 a.m. PTLocation: The Elizabeth Room, Westin St. FrancisA live webcast of the presentation will be accessible via the following URL: . , Jupiter, FL Date: Tuesday, October 30, 2018Time: 10:30 a.m. ETLocation: Track 2 - Preserve Ballroom B...
IMV Provides Update on Progress of its DPX-RSV Program
IMV Provides Update on Progress of its DPX-RSV Program New Proof of Concept Animal Health Data Validate RSV Vaccine Candidate’s Novel Mechanism of Action and Its Potential to Impact RSV Pathology DARTMOUTH, Nova Scotia, Sept. 27, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced results of ongoing research to further explore the novel mechanism of action (MOA) of its DPX-RSV vaccine candidate for respiratory syncytial virus (RSV). New data from a preclinical study highlighted the effects of two potential approaches ...
IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial ...
IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL Tumor Regressions Observed in Two of First Four Evaluable Patients, Including One Partial Response at First CT Scan DARTMOUTH, Nova Scotia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced details of the initial data from an ongoing investigator-sponsored Phase 2 clinical trial. In the study, investigators are evaluating IMV’s lead candidate, DPX-...
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to...
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications Clinical Expansion Marks Third Phase 2 Clinical Trial Combining IMV’s Lead Immunotherapy Candidate with Merck’s Marketed Checkpoint Inhibitor HALIFAX, Nova Scotia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low ...
IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova ...
IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in Dartmouth, Nova Scotia. , and , opened today’s event with remarks about the company’s milestones and successes. Other speakers included federal MP Darren Fisher, the Honourable Randy Delorey, Minister of Health and Wellness, and Dartmouth Centre Councillor Sam Austin. Emilie Chiasson, the Atlantic Regional Director of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.